Welcome to our dedicated page for Medicus Pharma news (Ticker: MDCX), a resource for investors and traders seeking the latest updates and insights on Medicus Pharma stock.
Medicus Pharma Ltd. (NASDAQ: MDCX) is a biotech and life sciences company whose news flow centers on clinical trial progress, regulatory milestones, strategic collaborations and capital markets activity. The company describes itself as a precision guided biotech/life sciences organization focused on advancing SkinJect™, an investigational microneedle therapy for basal cell carcinoma (BCC) of the skin, and Teverelix, a long-acting GnRH antagonist for hormone-driven conditions.
News updates frequently cover the SkinJect™ program, including Phase 2 study SKNJCT-003 in the United States, regulatory and ethics approvals to expand into the United Kingdom, and SKNJCT-004 in the United Arab Emirates. Releases also highlight interactions with the U.S. Food and Drug Administration (FDA), such as Type C meeting feedback supporting a 505(b)(2) regulatory pathway and the filing of an FDA Commissioner’s National Priority Voucher (CNPV) application for SKNJCT-003.
Another major theme in MDCX news is the Teverelix pipeline, added through the acquisition of Antev Limited. Company communications describe prior Phase 1 and Phase 2a data, FDA guidance on Phase 3 design, and plans to use AI-enabled analytics—via an engagement with Reliant AI Inc.—to support upcoming Teverelix clinical studies. Additional coverage includes Phase 1 data in healthy female volunteers and acceptance of Teverelix research for presentation at a leading endocrinology conference.
Investors following MDCX news will also see announcements on collaborations, such as the Gorlin Syndrome Alliance partnership for compassionate access to SkinJect™ and a non-binding memorandum of understanding with Helix Nanotechnologies, Inc. around thermostable infectious disease vaccines. Capital markets updates, including warrant inducement agreements, standby equity purchase activity and debenture financings, are disclosed through press releases and Form 8-K filings.
This news page aggregates these developments so readers can review Medicus Pharma’s clinical, regulatory, partnering and financing announcements in one place.
Medicus Pharma (NASDAQ: MDCX) will ring the Nasdaq Opening Bell on January 22, 2026, marking one year as a Nasdaq-listed company. The company is advancing multiple Phase 2 catalysts, including SkinJect (D-MNA), which completed enrollment of 90 US patients in SKNJCT-003 and expects topline results in Q1 2026 with an end-of-Phase 2 meeting targeted in H1 2026. Medicus completed the Antev acquisition (Teverelix), holds FDA approvals for Phase 2b designs (40-patient APC; 390-patient AURr), and announced non-binding deals with HelixNano and Reliant AI to support development and AI-driven analytics.
Medicus Pharma (NASDAQ: MDCX) announces Phase 1 e-poster acceptance at AACE 2026 for Teverelix, reporting data from two randomized, placebo-controlled studies in 48 healthy premenopausal women. Key findings: rapid LH/FSH suppression within 24 hours, dose-dependent estradiol suppression with multiple participants in the Barbieri window (30–50 pg/mL), sustained hormone suppression up to two–three weeks at higher doses, stable bone turnover markers, and a favorable safety profile with no drug-related serious adverse events. The company plans Phase 2 genomics-informed endometriosis study and continues SkinJect™ Phase 2 (90 patients enrolled) with topline data expected Q1 2026.
Medicus Pharma (NASDAQ: MDCX) will present at Biotech Showcase 2026 on Jan 13, 2026 at 10:00 a.m. PT, discussing Phase 2 catalysts, partnering readiness, and regulatory strategy for SkinJect™ and recent portfolio additions.
Key facts: completed enrollment of 90 patients in SKNJCT-003, topline Phase 2 results expected in Q1 2026, FDA Type C feedback supporting a 505(b)(2) pathway, CNPV application submitted in Nov 2025, acquisition of Antev (Teverelix) and a non-binding LOI with Reliant AI.
Medicus Pharma (NASDAQ:MDCX) announced a non-binding LOI with Reliant AI on December 22, 2025 to develop an AI-driven clinical data analytics platform aimed at improving site selection, patient stratification, and enrollment forecasting for Teverelix and other programs.
Medicus completed the acquisition of Antev in August 2025 to add Teverelix and reported clinical milestones for SkinJect: 90 patients enrolled in SKNJCT-003, topline results planned Q1 2026, FDA Type C feedback supporting a 505(b)(2) pathway, and U.K. regulatory approvals for Phase 2 expansion.
Medicus Pharma (NASDAQ: MDCX) completed enrollment of 90 patients in its U.S. Phase 2 trial SKNJCT-003 testing Doxorubicin Microneedle Array (D-MNA) to non-invasively treat nodular basal cell carcinoma (BCC) across 9 U.S. sites. The company expects topline results in Q1 2026 and plans to request an End-of-Phase 2 (EOP2) meeting with the FDA in H1 2026. Prior data include a Q1 2025 interim showing >60% clinical clearance in 26 patients and Phase 1 safety/tolerability in 13 participants with 6 complete histologic responses. Recent milestones: positive FDA Type C feedback on a 505(b)(2) pathway, UK regulatory and ethics approvals to expand SKNJCT-003, first patient dosed in SKNJCT-004 UAE, a MoU with HelixNano, acquisition of Antev, and a collaboration with the Gorlin Syndrome Alliance for expanded access.
Medicus Pharma (NASDAQ:MDCX) entered a warrant inducement agreement to accelerate exercise of existing Series A and B warrants issued July 14, 2025. The investor agreed to reduce the warrants' exercise price to $1.92 and to immediately exercise all outstanding warrants to buy 2,680,000 common shares for gross proceeds of approximately $5.1 million before fees.
In exchange, Medicus will issue unregistered Series C and D warrants to purchase an additional 4,020,000 shares at $2.00 per share, exercisable under similar terms and expiring 5.5 years from issuance; registration of resale of those shares is to be filed with the SEC. Closing is expected on or about December 5, 2025, subject to customary conditions.
Medicus Pharma (NASDAQ: MDCX) appointed Carolyn Bonner as Chief Financial Officer in addition to her role as President, effective December 1, 2025, after she served as acting CFO since September 12, 2025.
Key program updates: a Phase 2 U.S. trial SKNJCT-003 reported a March 2025 interim analysis showing >60% clinical clearance after >50% of a 60-patient target were randomized; FDA Type C feedback in September 2025 supported a 505(b)(2) pathway; first patient treated in SKNJCT-004 (UAE) in October 2025; full UK regulatory and ethical approvals for SKNJCT-003 were received in November 2025. The company completed acquisition of Antev in August 2025.
Medicus Pharma (Nasdaq: MDCX) announced clinical and corporate developments on Nov 24, 2025 focused on next‑generation prostate and skin cancer therapies.
Key points: Acquisition of Antev (Aug 2025) advancing Teverelix, a long‑acting GnRH antagonist with Phase 2a data showing 97.5% probability of castrate testosterone suppression (50 patients) and prior FDA written guidance supporting Phase 3 design. The company also reports SkinJect™ microneedle program progress: Phase 1 safety with 6 complete histologic responses (March 2021), ongoing SKNJCT‑003/004 trials, UK regulatory approvals to expand SKNJCT‑003 (Nov 2025), and a GSA collaboration for Expanded Access IND (Oct 2025).
Medicus Pharma (NASDAQ: MDCX) announced it filed a FDA Commissioner’s National Priority Voucher (CNPV) application on Nov 17, 2025 for SkinJect’s SKNJCT-003, a dissolvable doxorubicin microneedle array (D-MNA) to non-invasively treat basal cell carcinoma (BCC).
Key program facts: SKNJCT-003 is a randomized, double-blind Phase 2 trial (started Aug 2024) expanded to 90 subjects, reported a March 2025 interim showing >60% clinical clearance (preliminary), and received positive FDA Type C feedback on a 505(b)(2) pathway in Sept 2025. The company received UK regulatory and ethics approvals in Nov 2025 and began SKNJCT-004 in UAE (36 patients).
Medicus Pharma (NASDAQ:MDCX) reported Q3 2025 corporate and financial updates including clinical progress, an acquisition, patient-access initiatives, and financing activity.
Key points: SKNJCT-003 (Phase 2 D-MNA for basal cell carcinoma) has randomized >75% of a 90-patient target and received FDA Type C feedback supporting a 505(b)(2) pathway; UK MHRA/HRA/WREC approvals were received to expand the study and the first patient was treated in a UAE SKNJCT-004 study. Medicus completed the acquisition of Antev (Teverelix) in August 2025. Q3 cash was $8.7M after $10.4M aggregate net proceeds; Q3 operating expenses were $15.4M and net loss was $16.0M.